Market Cap | 1.04B | P/E | - | EPS this Y | -0.30% | Ern Qtrly Grth | - |
Income | -258.54M | Forward P/E | -5.30 | EPS next Y | -5.10% | 50D Avg Chg | -4.00% |
Sales | 1.39M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 2.00% |
Dividend | N/A | Price/Book | 3.69 | EPS next 5Y | - | 52W High Chg | -22.00% |
Recommedations | 1.80 | Quick Ratio | 15.96 | Shares Outstanding | 80.04M | 52W Low Chg | 26.00% |
Insider Own | 2.08% | ROA | -28.27% | Shares Float | 74.60M | Beta | 0.64 |
Inst Own | 106.72% | ROE | -47.66% | Shares Shorted/Prior | 6.11M/6.47M | Price | 19.17 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 483,441 | Target Price | 70.38 |
Oper. Margin | -20,747.62% | Earnings Date | Nov 5 | Volume | 565,841 | Change | -1.44% |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
JMP Securities | Market Outperform | Sep 27, 24 |
Cantor Fitzgerald | Overweight | Sep 16, 24 |
HC Wainwright & Co. | Buy | Aug 9, 24 |
Oppenheimer | Outperform | Aug 9, 24 |
JP Morgan | Overweight | Jul 9, 24 |
Piper Sandler | Overweight | Jul 2, 24 |
HC Wainwright & Co. | Buy | Jun 28, 24 |
JMP Securities | Market Outperform | Jun 4, 24 |
Oppenheimer | Outperform | Jun 4, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Jan 25 | Sell | 37.26 | 3,000 | 111,780 | 73,298 | 01/26/24 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Dec 26 | Sell | 35.89 | 3,000 | 107,670 | 79,298 | 12/27/23 |
Pizzuti Dana | Chief Med and Dev Of.. Chief Med and Dev Officer | Dec 21 | Sell | 34.57 | 9,583 | 331,284 | 5,911 | 12/22/23 |
Pizzuti Dana | Chief Med and Dev Of.. Chief Med and Dev Officer | Dec 21 | Option | 16.89 | 9,583 | 161,857 | 15,494 | 12/22/23 |
Struthers Richard Scott | President & CEO President & CEO | Nov 02 | Sell | 30.26 | 200,000 | 6,052,000 | 135,522 | 11/06/23 |
Struthers Richard Scott | President & CEO President & CEO | Nov 02 | Option | 9.28 | 200,000 | 1,856,000 | 334,604 | 11/06/23 |
Wilson Marc | CFO CFO | Nov 01 | Sell | 28.75 | 10,000 | 287,500 | 95,601 | 11/03/23 |
Wilson Marc | CFO CFO | Nov 01 | Option | 9.28 | 10,000 | 92,800 | 105,601 | 11/03/23 |
Krasner Alan Seth | Chief Medical Office.. Chief Medical Officer | Oct 17 | Sell | 30 | 7,000 | 210,000 | 43,210 | 10/19/23 |
Krasner Alan Seth | Chief Medical Office.. Chief Medical Officer | Oct 17 | Option | 12.01 | 7,000 | 84,070 | 50,210 | 10/19/23 |
Wilson Marc | CFO CFO | Jun 20 | Sell | 19.97 | 30,922 | 617,512 | 95,158 | 06/21/23 |
Wilson Marc | CFO CFO | Jun 20 | Option | 9.28 | 20,000 | 185,600 | 115,158 | 06/21/23 |
Struthers Richard Scott | President & CEO President & CEO | Jun 16 | Sell | 20.81 | 50,000 | 1,040,500 | 680,805 | 06/21/23 |
Vivaldi Coelho Rogerio | Director Director | Jun 08 | Buy | 22.06 | 5,000 | 110,300 | 5,000 | 06/09/23 |
Pizzuti Dana | Chief Development Of.. Chief Development Officer | Apr 03 | Sell | 16.15 | 8,212 | 132,624 | 4,500 | 04/05/23 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Oct 03 | Sell | 19.64 | 3,126 | 61,395 | 97,472 | 10/05/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Sep 07 | Sell | 21.0017 | 1,042 | 21,884 | 104,766 | 09/09/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | May 02 | Sell | 20.096 | 3,247 | 65,252 | 107,598 | 05/04/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Apr 18 | Sell | 25.81 | 5,664 | 146,188 | 110,845 | 04/21/22 |
PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Apr 18 | Buy | 22.22 | 157,515 | 3,499,983 | 5,321,032 | 04/18/22 |
Struthers Richard Scott | President & CEO President & CEO | Apr 13 | Sell | 26.49 | 138,643 | 3,672,653 | 730,805 | 04/15/22 |
Struthers Richard Scott | President & CEO President & CEO | Apr 05 | Sell | 25.3418 | 21,357 | 541,225 | 869,448 | 04/07/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Apr 04 | Sell | 23.9735 | 9,000 | 215,762 | 116,509 | 04/06/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Mar 31 | Sell | 21.43 | 8,328 | 178,469 | 125,509 | 04/01/22 |
Madan Ajay | Chief Development Of.. Chief Development Officer | Feb 28 | Sell | 19.88 | 9,000 | 178,920 | 176,995 | 03/02/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Feb 28 | Sell | 19.73 | 3,123 | 61,617 | 136,960 | 03/02/22 |
Madan Ajay | Chief Development Of.. Chief Development Officer | Feb 07 | Sell | 17.8275 | 13,411 | 239,085 | 172,045 | 02/09/22 |
Krasner Alan Seth | Chief Medical Office.. Chief Medical Officer | Jan 19 | Option | 12.01 | 6,700 | 80,467 | 15,011 | 01/21/22 |
Krasner Alan Seth | Chief Medical Office.. Chief Medical Officer | Jan 19 | Sell | 21.21 | 6,700 | 142,107 | 8,311 | 01/21/22 |
Betz Stephen F. | Chief Scientific Off.. Chief Scientific Officer | Nov 05 | Sell | 28.19 | 16,500 | 465,135 | 161,715 | 11/09/21 |